Oxford-Emergent Tuberculosis Consortium Signs Commercial License Agreement with Vivalis to Explore Production Of MVA85A TB Vaccine Candidate Using EB66(R) Cell Line
he Oxford-Emergent Tuberculosis Consortium Ltd., a joint venture between the University of Oxford and Emergent BioSolutions Inc. (NYSE:EBS), announced today the signing of a commercial license...
Oxford-Emergent Tuberculosis Consortium Signs Commercial License Agreement With ProBioGen To Explore Production Of MVA85A TB Vaccine Candidate Using AGE1.CR.pIX(R) Cell Line
he Oxford-Emergent Tuberculosis Consortium Ltd., a joint venture between the University of Oxford and Emergent BioSolutions Inc. (NYSE:EBS), announced today the signing of a commercial license...
New TB Vaccine Candidate Enters Phase IIb Proof-of-Concept Trial in South Africa
The Aeras Global TB Vaccine Foundation, the Oxford-Emergent Tuberculosis Consortium Ltd. ("the Consortium"), Isis Innovation Ltd., the Wellcome Trust and the University of Cape Town (UCT) announce...
HHS Extends Deadline for Bidders in Competitive Range for Recombinant Anthrax Vaccine (rPA) Contract to Submit Development Plan to FDA for Review to June 15, 2009
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Department of Health and Human Services (HHS) issued an additional amendment to its request for proposal for an Anthrax...
Emergent BioSolutions to Release First Quarter 2009 Financial Results and Conduct a Conference Call on May 7, 2009
Emergent BioSolutions Inc. (NYSE:EBS) announced today it will report financial results for first quarter 2009 on Thursday, May 7, 2009, after market...
HHS Requires Bidders in Competitive Range for Recombinant Anthrax Vaccine (rPA) Contract to Submit Development Plan to FDA for Review
Emergent BioSolutions Inc. (NYSE:EBS) announced today that late on April 15th, HHS requested that each bidder in the competitive range for the rPA contract submit its product development plans to FDA...
Emergent BioSolutions Announces Commencement of Phase I/II Clinical Trial of Anthrax Immune Globulin for Treating Anthrax Disease
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Phase I/II clinical trial for its Anthrax Immune Globulin (AIG) therapeutic candidate has commenced with the initial treatment given to...
Emergent BioSolutions Reports Financial Results for Full Year 2008
Emergent BioSolutions Inc. (NYSE:EBS) announced today its financial results for the fourth quarter and full year ended December 31,...
Emergent BioSolutions to Webcast Presentation at the Cowen & Co. 29th Annual Health Care Conference on Tuesday, March 17, 2009
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Cowen & Co. 29th Annual Health Care Conference scheduled for Tuesday, March 17, 2009...
Emergent BioSolutions Announces That BioThrax (Anthrax Vaccine Adsorbed) Receives Market Authorization in India
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Drugs Controller General of India (DCGI) has issued a registration certificate for BioThrax® (Anthrax Vaccine Adsorbed), which enables...
Emergent BioSolutions to Release Full Year 2008 Financial Results and Conduct a Conference Call on March 5, 2009
Emergent BioSolutions Inc. (NYSE: EBS) announced today it will report financial results for full year 2008 on Thursday, March 5, 2009, after market...
Emergent BioSolutions Provides Preliminary 2008 Financial Results and Guidance for 2009
Emergent BioSolutions Inc. (NYSE: EBS) announced today preliminary, unaudited financial results for 2008 and guidance for...